A connected chin strap that detects teeth clenching at night, technology born in post-stroke neurorehabilitation, 1,500 devices sold since June and several stock-outs in its very first summer. A look at family-backed funding in healthtech, and at a go-to-market that now has to reach people who don't yet know they're affected.
In mid-October, Bruxless announced a €4 million equity contribution from its family shareholders. No venture capital fund is joining the cap table: existing financial partners are stepping up their support. Based in Manosque, in the Alpes-de-Haute-Provence region of southern France, the company has been selling a connected chin strap since June that detects teeth clenching during sleep and responds with vibrations designed to help the jaw relax. The funds will support industrialization, R&D, commercial development and team growth.
At Uclic, we like to go beyond the press release. I spoke by video with Charles Collinot, Commercial Director of Bruxless, who was sitting that day in the offices of Techno Concept, the parent company. Mid-call, he grabbed a headset to show me on screen: it's much smaller than you'd imagine. He talked about the technology, a first commercial summer that was more intense than expected, and how Bruxless plans to reach people who often can't yet put a name to what they're going through. People like, as I realized during the call, the author of these lines.
A reflex that current solutions work around
Bruxism is the involuntary clenching or grinding of the teeth. According to Charles Collinot, 90% of episodes happen at night, although some people also do it during the day, at work for example.
The most common solutions, such as mouth guards or botulinum toxin injections, mainly aim to limit the damage, starting with enamel wear. Charles Collinot is careful not to pit them against his product.
“We don't criticize existing solutions in any way.”
He does, however, point to a limitation of mouth guards for severe bruxers.
“For many people considered severe bruxers, having a device in the mouth like a mouth guard pushes them to bite down on it. You protect the teeth a little, but the clenching itself can be amplified.”
Bruxless approaches the problem from the other end: acting on the reflex itself.
“The idea behind Bruxless isn't just to limit damage to the teeth. It's to try to deprogram bruxism from the brain, by sending it messages until episodes are reduced as much as possible.”
Post-stroke rehabilitation technology, adapted to the jaw
Bruxless was founded in 2021 within a family business. Charles Collinot works alongside his father, Guillaume Collinot, the company's founder and president, whose project grew out of a personal experience of bruxism.
The technology comes from Techno Concept, the parent company, which owns functional proprioceptive stimulation (FPS). Techno Concept has used it for years in neurorehabilitation across many conditions, for example after a stroke or a serious accident, after loss of use of a limb, for people in a coma, or with Parkinson's disease and ALS.
“We took this technology and adapted it to bruxism. It works the same way.”
In practice, the headset is worn like a chin strap, with sensors positioned over the masseters, the muscles that close the jaw. Each time it's used, a short calibration measures their activity: eight seconds with the jaw relaxed, then eight seconds with the jaw clenched. The headset thus learns each user's own resting and effort values.
“Every case of bruxism is different: the symptoms, the consequences, the profiles. We needed a single tool that adapts to everyone.”
During the night, as soon as the measured pressure goes beyond resting values, the headset emits a targeted vibration.
“We send a vibration, which sends a message to the brain, which sends a relaxation signal back to the muscle. It's the repetition over time that reduces episodes.”
The idea is to give the brain back information it no longer perceives during sleep.
“At night, it's an ingrained reflex. We make the brain aware that it's clenching, precisely so that it lets go.”
Other connected devices exist on the market, based on biofeedback. For Charles Collinot, the difference lies in the approach: Bruxless relies on a neurorehabilitation principle rather than a simple signal sent to the muscle.
A family contribution rather than a fundraise
Charles Collinot makes the point right at the start of our conversation.
“It's not really a fundraise. It's a contribution from our financial partners, who were already on board.”
The €4 million comes from the company's family shareholders. It arrives as Bruxless moves from launch to scale: industrialization is set to evolve, and the teams are growing to keep up with demand.
Bruxless is still sold as a wellness product, not as a medical device. Medical device certification, in Europe as with the US FDA, remains a goal, but it takes time, money and resources. For now, the priority is the launch.
A first summer of running out of headsets
Pre-orders opened in February 2025. The first headsets shipped in June 2026, when sales opened to everyone.
Since June, 1,500 devices have been sold, not counting pre-order customers. A volume the team hadn't anticipated.
“We ran out of headsets several times over the summer. They're good problems to have, but we had underestimated demand.”
Bruxless had planned to ramp up gradually, to stay on top of customer follow-up. The company therefore shipped in successive batches, and it was only in mid-October that shipments caught up with orders. The shareholders' contribution is meant precisely to make it possible to produce and support customers at this pace.
€699, and few objections on price
The headset sells for €699, with an option to pay in four installments and a 30-night trial. A price that, according to Charles Collinot, holds few people back.
“We get very little pushback on price.”
The explanation lies in the profile of early customers. They are often severe bruxers, already diagnosed, who have tried several solutions: mouth guards, injections, sessions with a physiotherapist, osteopath, sophrologist or psychologist.
“For them, bruxism is very expensive every year. The math is quick: a headset that genuinely relieves your bruxism is far more cost-effective in the long run than carrying on like that.”
Practitioners as recommenders, without a prescription
This is the part that interests us most at Uclic. Summer sales came from several sources: people who signed up during pre-orders, media coverage, people who were looking for a bruxism solution on their own, and Meta and Google campaigns running continuously.
The channel Charles Collinot wants to develop first is healthcare professionals. He handles it himself: before Bruxless, he worked at an AI-in-healthcare company, where he built a network of practitioners, especially dentists.
Its status as a wellness product sets the framework. A practitioner can recommend Bruxless but not prescribe it, and the headset is reimbursed neither by French national health insurance nor by supplementary insurers. The need, however, is very real.
“For healthcare professionals, bruxism is a scourge, because apart from mouth guards there isn't really a solution.”
Charles Collinot gives the most telling example.
“A dentist redoing implants for a patient who really clenches or grinds their teeth has a problem: within six months, the patient can break all their implants.”
The launch triggered many requests from practitioners. Bruxless sends them a headset so they can try it themselves, with tests that take time, since the first results don't show up overnight. The website also has a dedicated area for professionals, with a discount code to pass on to their patients.
“For me, it's essential. The relationship between patient and practitioner has to continue.”
A month of support after purchase
Bruxless doesn't stop at delivery. A dedicated customer relations team follows each new user during their first month, to make sure they've fully understood how the headset works. Charles Collinot compares them to customer success managers.
“You buy a headset, and it's not: you receive it and goodbye. There's real support and follow-up during the first month.”
This support comes up often in customer feedback, and the team keeps refining its processes to make them smoother.
Reaching people who don't know yet
The broadest market is still to be won. According to estimates cited by Charles Collinot, around one in five people experience bruxism, in France as worldwide. Many don't know it.
“Many people have never been diagnosed. They have headaches, vision problems, neck pain, they go through lots of tests, and don't realize it comes from the masseters.”
Today, Bruxless's acquisition mainly targets the bottom of the funnel: people who already know they're bruxers and are looking for a solution. A few more educational ads have been tested and reached a wide audience, but this audience will require a longer sales cycle.
The approach being considered goes through diagnosis. The website already offers a questionnaire that estimates your level of bruxism in a few questions. Eventually, it should direct people who have been looking for a solution for years toward a partner professional. The diagnosis made during the consultation can then lead to a recommendation of Bruxless. Every person made aware also strengthens the value of the practitioner network.
Charles Collinot insists on the underlying message.
“If you recognize yourself in these symptoms, get diagnosed, and don't wait too long. Once bruxism is ingrained in you, it's hard to get rid of.”
Confirming the launch, then opening up Europe
Over the next 12 to 18 months, the goal is first to confirm the launch and the positive feedback from early users, while continuing to invest in customer relations. Bruxless is also starting to work on the European market: the company receives many requests from neighboring countries. Work on certifications is set to continue in parallel.
Key takeaways
Three lessons from this conversation that go beyond healthtech.
First: a successful launch is also won in operations. Bruxless had planned to ramp up gradually to stay on top of customer follow-up, and ran out of stock several times in its very first summer. The shareholders' contribution first funds the ability to produce and support customers at the pace of demand.
Second: price is compared with the cost of the problem. Many of Bruxless's early customers have already spent money on mouth guards, injections and various sessions: they compare the €699 headset with what bruxism costs them every year, not with the price of a connected device.
Third: the market looking for a solution is smaller than the one that doesn't know it's affected. If one person in five is affected and many don't know it, bottom-of-funnel acquisition only reaches part of the target. For a wellness product that can't be prescribed, what comes next is public education and practitioners, who turn a diagnosis into a recommendation.
We'll be keeping a close eye on how Bruxless builds its network of healthcare professionals and takes its first steps in Europe.
Bruxless at a glance
- Headquarters: Manosque (Alpes-de-Haute-Provence, France).
- Founded in 2021, subsidiary of Techno Concept, a neurorehabilitation specialist.
- Leadership: Guillaume Collinot, founder and president; Charles Collinot, Commercial Director.
- Product: connected chin strap that detects masseter activity and responds with calibrated vibrations (functional proprioceptive stimulation), with a companion app.
- Status: wellness product, designed and made in France.
- Price: €699, payable in four installments, 30-night trial.
- Sales: pre-orders since February 2025, first deliveries and general availability in June 2026.
- Traction: 1,500 devices sold since June 2026, in addition to pre-orders.
- Funding: €4M equity contribution from family shareholders (October 2026).
- Website: bruxless.com
Article published by Uclic, growth marketing and AI agency. Interview conducted by Alexis Christine-Amara on October 22, 2026.